Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria

Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria

Aeglea BioTherapeutics, Inc.has announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to ACN00177 for the treatment of Homocystinuria. Aeglea initiated a Phase 1/2 clinical trial earlier this year to investigate ACN00177 for the treatment of Homocystinuria. Read the Press Release here.